CD276 and neoplasm: To target CD276 with immunotherapy in SCLC, we evaluated two different CAR-constructs, which differ in their mechanism of tumor targeting: dCAR-T, which directly target CD276; and AdCAR-T, which indirectly target CD276 via an AM.